TransMedics Group Inc (TMDX)
Cash ratio
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 394,812 | 201,182 | 25,580 | 24,581 | 20,092 |
Short-term investments | US$ in thousands | — | — | 66,920 | 101,019 | 60,608 |
Total current liabilities | US$ in thousands | 54,934 | 23,661 | 23,238 | 11,879 | 16,115 |
Cash ratio | 7.19 | 8.50 | 3.98 | 10.57 | 5.01 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($394,812K
+ $—K)
÷ $54,934K
= 7.19
The cash ratio of TransMedics Group Inc has exhibited variation in recent years, ranging from 3.98 to 10.57. In 2023, the cash ratio decreased to 7.19 from 8.50 in 2022, indicating a decline in the company's ability to cover its short-term liabilities solely with its available cash and cash equivalents. However, the ratio remains relatively healthy, suggesting that the company still possesses a significant amount of liquid assets compared to its current liabilities. Further analysis would be needed to understand the factors contributing to this trend and evaluate the overall liquidity position of TransMedics Group Inc.
Peer comparison
Dec 31, 2023